Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)

National University Health System (NUHS)

Status

Unknown

Conditions

Epithelial Ovarian Cancer

Organoids

HNSCC

Colorectal Cancer

Treatments

Procedure: Blood sampling

Procedure: Tumor Core Biopsy

Study type

Interventional

Funder types

Other

Identifiers

NCT04279509

MC01/01/19

Details and patient eligibility

About

This is a single-centre study based on the Simon 2-stage optimax design: 12 patients will be enrolled initially (Stage I), which will then be expanded to a further 13 patients (Stage II) if 3 or more patients enrolled in stage I of the study achieve an objective response with the chemotherapeutic agent selected by the drug screen assay. A total of 25 patients will be included in both stages of study.

Patients enrolled on study will undergo a fresh biopsy of tumour lesion to obtain cells that will be used to generate patient-derived tumour organoids based on the Invitrocue technology. Organoids will then be subjected to a 10-drug panel screening including: 5-fluorouracil, carboplatin, cyclophosphamide, docetaxel, doxorubicin, gemcitabine, irinotecan, oxaliplatin, paclitaxel and vinorelbine. A further 5 drugs (etoposide, ifosfamide, methotrexate, pemetrexed and topotecan) will be screened if sufficient organoids are grown from the biopsy samples within the screening period.

Physicians will be informed of the results, and choice of chemotherapy will be based on an IRS score of 70% or above. If more than 1 candidate drug with IRS of 70% or above is identified, the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function.

Full description

Investigators hypothesize that high-throughput screening on patient-derived tumour organoids can be used as an adjunct tool to aid treatment selection in patients with cancer. Using the IRS, drugs with high IRS (defined as a score of 70% and above) will have a high probability of inducing objective response (either a complete or partial response by RECIST criteria) in patients with refractory cancers. Conversely, IRS of drugs for which the patients have been treated and experienced clinical progression on will be low (defined as a score of 50% or below).

Primary Objectives

-To prospectively determine if a high-throughput drug screen assay using patient tumour-derived organoids can accurately select a chemotherapeutic agent that results in objective response in patients with refractory solid tumours

Secondary Objectives

To assess the IRS measured on tumour-derived organoid drug screen assay of chemotherapeutic agents to which patients had previously progressed on clinically
To assess changes in IRS pre and post-chemotherapy treatment

Enrollment

35 estimated patients

Sex

All

Ages

21 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 21 years.
Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
ECOG 0-1.
At least 1 tumour lesion (primary or metastatic) amenable to fresh biopsy
At least 1 measurable tumour lesions based on RECIST 1.1 criteria
Estimated life expectancy of at least 12 weeks.
Has documented progressive disease from last line of therapy.
Able to wait at least 4 to 6 weeks before initiating the next line of anti-cancer therapy.
Has received at least 2 line of palliative systemic therapy:

(i) Breast cancer: must have received prior anthracyclines and taxanes in the neoadjuvant, adjuvant or palliative setting, unless either of these drugs were contraindicated due to organ dysfunction and/or comorbidities (ii) Ovarian cancer: must have received prior taxanes and platinums in the neoadjuvant, adjuvant or palliative setting (iii)HNSCC: must have received prior platinums, taxanes, and 5-fluorouracil in the neoadjuvant, adjuvant or palliative setting (iv)Colorectal cancer: must have received prior 5-fluorouracil, oxaliplatin and irinotecan in the neoadjuvant, adjuvant or palliative setting
Adequate organ function including the following:

(i)Bone marrow:
- Absolute neutrophil (segmented and bands) count (ANC) ≥ 1.5 x 109/L
- Platelets ≥100 x 109/L
- Hemoglobin ≥ 8 x 109/L

(ii) Hepatic:

Bilirubin ≤ 1.5 x upper limit of normal (ULN),
ALT or AST ≤ 2.5x ULN,(or ≤ 5X with liver metastases)

(iii) Renal:

◦Creatinine ≤ 1.5x ULN

Signed informed consent from patient or legal representative.
Able to comply with study-related procedures.

Exclusion criteria

Pace of cancer progression requiring commencement of anti-cancer therapy within 4 to 6 weeks.
Treatment within the last 30 days with any investigational drug.
Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.
Major surgery within 28 days of study drug administration.
Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
Pregnancy.
Breast feeding.
Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
Active bleeding disorder or bleeding site.
Non-healing wound.
Poorly controlled diabetes mellitus.
Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
Symptomatic brain metastasis.
History of significant neurological or mental disorder, including seizures or dementia.